利用NSCLC患者ROSE细胞学制片进行EGFR、KRAS、PIK3CA基因检测可行性的研究

摘要

Objective To explore the feasibility of EGFR, KRAS and PIK3CA mutation analysis on rapid on-site evaluation (ROSE)cytological slides in patients with non-small cell lung cancer and its clinical value. Methods Seventy-five cases of ROSE cytological slides and paired histological specimens were collected in Tianjin Medical University General Hospital. xTAG70plex liquidchip technology was used to analyze the gene mutations of the samples.Results The KRAS mutation was found in histological specimen but not in ROSE cytological slides in one case. The mutation results were the same in histological specimen and ROSE cytological slides in other cases.The consistent rates of the EGFR mutation and KRAS mutation were 100% and 98.7%,respectively. Conclusion Our study demonstrates that xTAG70plex liquidchip technology can be used for the mutation analysis of EGFR,KRAS and PIK3CA genes in non-small cell lung cancer on ROSE cytological slides.%目的 探讨应用xTAG70plex液相芯片技术对非小细胞肺癌(NSCLC)患者的快速现场评价(ROSE)细胞学制片进行EGFR、KRAS和PIK3CA基因检测的可行性及其临床价值.方法 纳入就诊于天津医科大学总医院行支气管镜检查并最终病理诊断为NSCLC的患者75例ROSE细胞学制片和配对的组织学标本,分别用xTAG70plex液相芯片进行EGFR、KRAS和PIK3CA基因突变检测.结果 除1例在组织学标本检出为KRAS突变而在配对的ROSE细胞学标本没有检测出来的病例,其他病例基因突变检测结果均相同,两种标本EGFR基因突变检测结果一致率为100%,KRAS基因突变检测结果一致率为98.7%.结论 xTAG70plex液相芯片技术可以有效地检测ROSE细胞学制片EGFR、KRAS和PIK3CA的基因突变状态,对于NSCLC患者,ROSE细胞学制片可以作为组织学替代标本进行基因检测.